BMRA
Biomerica, Inc.
Set alert
- YTD
- -31.75%
- 1 year
- -37.68%
- Open
- 1.70
- Prev close
- 1.74
- Mkt cap
- 7.91M
- Vol
- 10.22K
- Avg vol
- 71.60K
- EPS
- -1.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.68
- High
- 1.74
- Forward P/E
- 0.71
- Beta
- -1.14
- Short ratio
- 0.76
- Inst. own
- 12.36%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 21, 2025
- 50-d avg
- 0.3326
- 200-d avg
- 0.48235
- 1y target
- 0.00
Key statistics
- Market cap
- 4.68M
- Enterprise value
- 2.58M
- Trailing P/E
- 0.00
- Forward P/E
- 0.71
- PEG ratio
- 0.00
- Price / sales
- 0.85
- Price / book
- 0.87
- EPS (TTM)
- -0.37
- Beta
- -1.14
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -111.85%
- Revenue (TTM)
- 5.51M
- Revenue growth
- 5.50%
- Free cash flow
- -2.66M
- Total cash
- 2.82M
- Total debt
- 707.00K
- Return on equity
- -76.48%
- Shares outstanding
- 16.82M
- Short % of float
- 9.13%
- 50-day average
- 0.3326
- 200-day average
- 0.48235
Analyst view
Consensus: none
Next earnings
Jan 21, 2025
Expected Jan 21, 2025. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 21, 2025 | Nov 1, 2024 | 0.00 | — | — | — |
| Oct 15, 2024 | Aug 1, 2024 | 0.00 | -0.08 | — | — |
| Aug 28, 2024 | May 1, 2024 | 0.00 | -0.09 | — | — |
| Apr 12, 2024 | Feb 1, 2024 | 0.00 | -0.11 | — | — |
| Jan 16, 2024 | Nov 1, 2023 | 0.00 | -0.09 | — | — |
| Oct 12, 2023 | Aug 1, 2023 | 0.00 | -0.07 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2020 | Aegis Capital | main | — | Buy |
| Sep 4, 2020 | Aegis Capital | main | — | Buy |
| Aug 21, 2020 | Aegis Capital | init | — | Buy |
| Dec 17, 2018 | B. Riley Securities | main | Buy | Buy |
About Biomerica, Inc.
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops, markets, and sells COVID-19 diagnostic tests to indicate if a person has been infected by COVID-19. The company was incorporated in 1971 and is headquartered in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- biomerica.com
News
- Biomerica Reports First Quarter Fiscal 2027 Financial Results
- Biomerica Q1 EPS $(0.37), Sales $1.265M Down From $1.380M YoY
- Biomerica Files $250M Shelf Registration Statement For Mixed Securities Offering
- Biomerica Files Prospectus Covering Resale Of Up To 1,403,705 Shares Of Common Stock By Selling Stockholders
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Head-To-Head Survey: Biomerica (NASDAQ:BMRA) versus Cytosorbents (NASDAQ:CTSO)
- Biomerica Q4 EPS $(0.38) Up From $(0.69) YoY, Sales $875.000K Up From $749.000K YoY
- Biomerica Reports Fiscal 2026 Year-End Financial Results
- Deal Dispatch: Carets Corp Explores Strategic Alternatives, nVent Electric Buys Maverick Power for $1.75 Billion, BioXcel Bankruptcy
- Biomerica Commences ~$2.23M Private Placement Of 1.394M Shares At $1.60 Per Share
Your note
Sign in to keep a note on BMRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARBIERI ALLEN | Officer and Director | Stock Award(Grant) | Dec 12, 2024 | 188,337 |
| COSTE CATHERINE | Director | Stock Award(Grant) | Dec 12, 2024 | 128,790 |
| EMERSON JANE | Director | Stock Award(Grant) | Dec 12, 2024 | 156,000 |
| IRANI ZACKARY S | Chief Executive Officer | Stock Award(Grant) | Dec 12, 2024 | 1,270,560 |
| LU GARY | Chief Financial Officer | Stock Award(Grant) | Dec 12, 2024 | 155,000 |
| MOATAZEDI DAVID | Director | Stock Award(Grant) | Dec 12, 2024 | 85,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Granahan Investment Management LLC | 3.14% | 527,461 | 146.63K | Sep 29, 2024 |
| Russell Investments Group, Ltd. | 1.34% | 225,435 | 62.67K | Sep 29, 2024 |
| Vanguard Group Inc | 1.00% | 169,010 | 46.98K | Sep 29, 2024 |
| Blackrock Inc. | 0.89% | 149,081 | 41.44K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.74% | 124,363 | 34.57K | Sep 29, 2024 |
| UBS Group AG | 0.55% | 91,692 | 25.49K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| JNL Series Trust-JNL/Multi Manager Small Cap GrowthFd | 1.26% | 211,736 | 58.86K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.00% | 169,010 | 46.98K | Sep 29, 2024 |
| USAA Mutual Fund Tr-Small Cap Stock Fund | 0.49% | 81,784 | 22.73K | Jul 30, 2024 |
| Fidelity Extended Market Index Fund | 0.47% | 78,873 | 21.93K | Oct 30, 2024 |
| Perritt Ultra MicroCap Fund | 0.42% | 70,000 | 19.46K | Jul 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 19,838 | 5.51K | Oct 30, 2024 |